Skip to content
    Clinical Trials

    Gedatolisib in HR-Positive/HER2-Negative Advanced Breast Cancer Post-CDK4/6 Progression

    Aziz Ullah and Muhammad AkhtarExpert opinion on pharmacotherapy

    Gedatolisib in HR-Positive/HER2-Negative Advanced Breast Cancer Post-CDK4/6 Progression
    Progression following CDK4/6 inhibitor therapy remains a substantial therapeutic challenge in hormone receptor-positive, HER2-negative advanced breast cancer. Gedatolisib, an FDA-approved pan-class I PI3K/mTORC1/2 inhibitor, introduces a treatment approach specifically for patients with disease lacking a detected PIK3CA mutation.
    In a review synthesizing pharmacology, safety, biomarkers, and clinical data through September 2026, evidence from the phase III VIKTORIA-1 trial evaluated gedatolisib-containing combinations against fulvestrant monotherapy. Median progression-free survival was 9.3 months with the triplet regimen of gedatolisib, fulvestrant, and palbociclib compared to 2.0 months with fulvestrant alone (hazard ratio 0.24). The doublet regimen of gedatolisib plus fulvestrant yielded a median progression-free survival of 7.4 months compared to 2.0 months with fulvestrant (hazard ratio 0.33). However, the study was not powered to directly compare the doublet and triplet regimens.
    Clinical implementation requires careful management of toxicities, as treatment delivery is complicated by stomatitis, metabolic adverse events, palbociclib-associated neutropenia, and a weekly intravenous dosing schedule. The authors emphasize that while gedatolisib expands post-CDK4/6 therapeutic options, optimal positioning requires individualized patient selection without assuming superiority of the triplet regimen. Long-term clinical value will depend on mature overall survival data, validated predictive biomarkers, comparative sequencing evidence, and upcoming results from the VIKTORIA-2 trial.

    Key Takeaways

    • In the phase III VIKTORIA-1 trial, median progression-free survival reached 9.3 months with gedatolisib plus fulvestrant and palbociclib versus 2.0 months with fulvestrant alone (hazard ratio 0.24).
    • Median progression-free survival was 7.4 months with gedatolisib plus fulvestrant versus 2.0 months with fulvestrant (hazard ratio 0.33), though the two experimental arms were not directly compared in a powered analysis.
    • Treatment delivery is complicated by stomatitis, metabolic toxicity, palbociclib-associated neutropenia, and the requirement for weekly intravenous administration.
    Read the original sourceExpert opinion on pharmacotherapy